Float Short %

1.13

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

0.15

EPS Last/This Y

EPS This/Next Y

Price

0.35

Target Price

2.25

Analyst Recom

1.4

Performance Q

-31.15

Relative Volume

0.58

Beta

0.12

Ticker: XAIR

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-01-23	XAIR	0.4172	0.00	0.01	5035
2025-01-24	XAIR	0.4273	0.00	0.00	5084
2025-01-27	XAIR	0.4052	0.00	0.00	5274
2025-01-28	XAIR	0.3829	0.00	0.00	5579
2025-01-29	XAIR	0.388	0.00	0.00	5621
2025-01-30	XAIR	0.3837	0.00	0.04	5629
2025-01-31	XAIR	0.3913	0.00	0.04	5654
2025-02-03	XAIR	0.3609	0.00	0.00	5744
2025-02-04	XAIR	0.392	0.00	0.03	5782
2025-02-05	XAIR	0.4083	0.00	0.03	5924
2025-02-06	XAIR	0.4007	0.00	0.00	6180
2025-02-07	XAIR	0.422	0.00	0.01	6503
2025-02-10	XAIR	0.4301	0.00	0.01	7070
2025-02-11	XAIR	0.4142	0.02	0.01	9173
2025-02-12	XAIR	0.376	0.02	0.11	9646
2025-02-13	XAIR	0.3714	0.02	0.32	9660
2025-02-14	XAIR	0.384	0.02	0.01	9685
2025-02-18	XAIR	0.363	0.02	0.00	9914
2025-02-19	XAIR	0.377	0.02	1.55	9971
2025-02-20	XAIR	0.3599	0.02	0.03	9974
2025-02-21	XAIR	0.3565	0.01	0.03	9877
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-01-23	XAIR	0.42	-	-	0.00
2025-01-24	XAIR	0.43	-	-	0.00
2025-01-27	XAIR	0.40	-	-	0.00
2025-01-28	XAIR	0.39	-	-	0.00
2025-01-29	XAIR	0.39	-	-	0.00
2025-01-30	XAIR	0.38	-	-	0.00
2025-01-31	XAIR	0.39	-	-	0.00
2025-02-03	XAIR	0.36	-	-	0.00
2025-02-04	XAIR	0.39	-	-	0.00
2025-02-05	XAIR	0.41	-	-	0.00
2025-02-06	XAIR	0.40	-	-	0.00
2025-02-07	XAIR	0.42	-	-	0.00
2025-02-10	XAIR	0.44	-	-	0.00
2025-02-11	XAIR	0.41	-	-	0.00
2025-02-12	XAIR	0.37	-	-	0.00
2025-02-13	XAIR	0.37	-	-	0.00
2025-02-14	XAIR	0.39	-	-	0.00
2025-02-18	XAIR	0.36	-	-	0.00
2025-02-19	XAIR	0.38	-	-	0.00
2025-02-20	XAIR	0.36	-	-	0.00
2025-02-21	XAIR	0.35	-	-	0.00
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-01-23	XAIR	45.66	154.91	1.87
2025-01-24	XAIR	45.66	154.91	1.87
2025-01-27	XAIR	45.66	154.91	1.87
2025-01-28	XAIR	45.66	154.91	1.56
2025-01-29	XAIR	45.65	154.91	1.56
2025-01-30	XAIR	45.66	154.91	1.56
2025-01-31	XAIR	45.65	154.91	1.56
2025-02-03	XAIR	45.66	165.11	1.56
2025-02-04	XAIR	42.37	165.11	1.56
2025-02-05	XAIR	42.37	165.11	1.48
2025-02-06	XAIR	42.38	165.11	1.48
2025-02-07	XAIR	42.38	165.11	1.48
2025-02-10	XAIR	42.38	39.26	1.48
2025-02-11	XAIR	42.38	39.26	1.48
2025-02-12	XAIR	42.37	39.26	1.31
2025-02-13	XAIR	34.47	39.26	1.13
2025-02-14	XAIR	34.46	39.26	1.13
2025-02-18	XAIR	31.13	38.46	1.13
2025-02-19	XAIR	31.13	38.46	1.13
2025-02-20	XAIR	30.45	38.46	1.13
2025-02-21	XAIR	30.46	38.46	1.13
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.15

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

30.46

Institutional Transactions

38.46

Beta

0.12

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.9

Max Drawdown 5-Year %

-98.1

Target Price

2.25

P/E

Forward P/E

PEG

P/S

10.24

P/B

1.48

P/Free Cash Flow

EPS

-1.05

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1730

Relative Volume

0.58

Return on Equity vs Sector %

-315.7

Return on Equity vs Industry %

-308.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Beyond Air, Inc.

Sector: Healthcare

Industry: Medical Devices

Employees: 107

Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

stock quote shares XAIR – Beyond Air Inc Stock Price stock today

news today XAIR – Beyond Air Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch XAIR – Beyond Air Inc yahoo finance google finance

stock history XAIR – Beyond Air Inc invest stock market

stock prices XAIR premarket after hours

ticker XAIR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: XAIR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y